OrthoPediatrics Corp. announced a distribution partnership with MY01 to expand access to Continuous Perfusion Sensing Technology for diagnosing acute compartment syndrome in children, focusing on improving trauma monitoring and patient outcomes.

OrthoPediatrics reported Q2 2025 revenue of $61.1 million, slightly below estimates, with continued growth in pediatric orthopedic devices. The company maintained its full-year revenue guidance and showed improvements in adjusted EBITDA, though still experiencing net losses.

OrthoPediatrics Corp., a company focused on pediatric orthopedics, announced its continued support of the 2025 Pediatric Orthopaedic Society of North America (POSNA) annual meeting as an Emerald Sponsor. The company highlighted its growing portfolio of pediatric-specific solutions, including OrthoPediatrics Specialty Bracing and Enabling Technologies.

OrthoPediatrics Corp. reported record preliminary unaudited revenue of $204.7 million in 2024, up 38% year-over-year. The company expects revenue to grow 15-18% in 2025 and adjusted EBITDA of $15-17 million.

Bruker Corporation announced the acquisition of Dynamic Biosensors GmbH, a company known for its development in biosensors. The acquisition is expected to strengthen Bruker's position in the pharma and biotech industries by leveraging its leading high-throughput Surface Plasmon Resonance portfolio and Dynamic Biosensors' unique instruments.

OrthoPediatrics Corp. (KIDS) has launched its Enabling Technologies division, which will leverage the company's core mission of addressing unmet pediatric needs in orthopedics. The new division is expected to differentiate KIDS' core business, generate sustainable revenue growth, and gain access to new markets and specialties beyond orthopedics.

OrthoPediatrics reported Q2 2024 revenue of $52.8 million, up 33.5% year-over-year, and EPS of -$0.23 compared to -$0.19 a year ago. The company's performance across key product categories was mixed compared to analyst estimates.

CVRx (CVRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

WARSAW, Ind., June 04, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS) a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President & Chief Executive Officer is scheduled to participate in a fireside chat at the Truist Securities MedTech Conference, being held in Boston, MA.

Reinforced Long-Term Commitment as Emerald Sponsor Reinforced Long-Term Commitment as Emerald Sponsor

7 analysts have expressed a variety of opinions on OrthoPediatrics (NASDAQ:KIDS) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 1 0 0 Last 30D 1 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 1 0 0 3M Ago 2 1 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for OrthoPediatrics, presenting an average target of $40.29, a high estimate of $50.00, and a low estimate of $32.00. Witnessing a positive shift, the current average has risen by 20.88% from the previous average price target of $33.33. Deciphering Analyst Ratings: An In-Depth Analysis An in-depth analysis of recent analyst actions unveils how financial experts perceive OrthoPediatrics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Mike Matson Needham Raises Buy $42.00 $37.00 David Turkaly JMP Securities Maintains Market Outperform $50.00 - Mike Matson Needham Maintains Buy $37.00 - Samuel Brodovsky Truist Securities Raises Hold $32.00 $31.00 Rick Wise Stifel Raises Buy $34.00 $32.00 Mike Matson Needham Maintains Buy $37.00 - David Turkaly JMP Securities Maintains Market Outperform $50.00 - Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related ...Full story available on Benzinga.com

While the top- and bottom-line numbers for OrthoPediatrics (KIDS) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.